Ar­a­vive merges with strug­gling Ver­sar­tis, gain­ing ac­cess to Nas­daq; Si­lence Ther­a­peu­tics CEO Ali Mor­taza­vi leaves the RNAi biotech

→ Right on the heels of its first clin­i­cal proof-of-mech­a­nism da­ta, Ar­a­vive Bi­o­log­ics an­nounced it will con­tin­ue the de­vel­op­ment of GAS6-AXL in­hibitor AVB-S6-500 as a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER